Quantum Leap Healthcare Collaborative Announces AstraZeneca's Olaparib And Durvalumab For The I-SPY 2 Trial For Breast Cancer
7 September 2018
Quantum Leap Healthcare Collaborative™ (QLHC) announced today that a new randomized, investigational treatment arm for the I-SPY 2 TRIAL™ includes the study of olaparib and durvalumab,
